Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc.

LRMR·NASDAQ

$3.20

-3.0%
HealthcareBiotechnology

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.

At a Glance

Live Snapshot
Market Cap$273.97M
EPS-2.2700
P/E Ratio-1.41
Earnings Date08/06/2026

lrmr

Common Stock

Last Annual Value

83.00K

3-Year CAGR

25%

5-Year CAGR

41%

10-Year CAGR

12%

Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. Competitors Analysis of Common Stock

LRMR · NASDAQ
CompanyCommon Stock
CAGR 3Y
CAGR 5Y
CAGR 10Y
83.00K
24.5%35.8%11.9% 
ALEC logo
Alector, Inc.
NASDAQ:ALEC
11.00K
11.2%6.6%N/A
10.00K
7.7%7.4%9.6%
3.00K
44.2%N/AN/A
2.00K
-56.9%-39.2%N/A
21.00K
44.2%39.3%N/A
59.00K
10.3%9.2%8.5%
77.00K
10.5%10.4%N/A
1.00K
N/AN/AN/A
KRRO logo
Korro Bio, Inc.
NASDAQ:KRRO
9.00K
4.0%-23.8%N/A
7.00K
32.6%33.1%N/A
Larimar Therapeutics, Inc.

Larimar Therapeutics, Inc. Fair Value Envelope

LRMR · NASDAQ

Our analysis suggests that LRMR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $3.2014, this represents a potential HIDDEN relative to our calculated worth for Larimar Therapeutics, Inc..

Intrinsic Value
Current Price: $3.2014